These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25374217)

  • 1. Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
    Gunduz S; Mutlu H; Goksu SS; Arslan D; Tatli AM; Uysal M; Coskun HS; Bozcuk H; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(20):8843-6. PubMed ID: 25374217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
    Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
    Raphael J; Le Teuff G; Hollebecque A; Massard C; Bahleda R; Margery J; Besse B; Soria JC; Planchard D
    Lung Cancer; 2014 Aug; 85(2):251-7. PubMed ID: 24882384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
    Lau B; Kumar S; Yan T; Burn J; Kennedy C; McLean J; Boyer M; McCaughan B; Kao S
    Lung Cancer; 2017 Sep; 111():75-78. PubMed ID: 28838403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
    Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
    Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
    Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
    Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
    J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
    Cihan YB; Ozturk A; Mutlu H
    Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
    Kasseyet S; Astoul P; Boutin C
    Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.
    Takuwa T; Hashimoto M; Matsumoto S; Kondo N; Kuribayash K; Nakano T; Hasegawa S
    Int J Clin Oncol; 2017 Oct; 22(5):857-864. PubMed ID: 28439676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
    Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.